<DOC>
	<DOCNO>NCT01123356</DOCNO>
	<brief_summary>The purpose research evaluate safety effectiveness drug lenalidomide ofatumumab treatment chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Treatment Chronic Lymphocytic Leukemia Patients Previously Exposed Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects must confirm diagnosis chronic lymphocytic leukemia ( CLL ) . 2 . Prior therapy least one regimen contain rituximab 3 . Age &gt; 18 year . 4 . Life expectancy great 12 month . 5 . ECOG performance status &lt; 2 6 . Patients must normal organ function define protocol . 7 . Patients must adequate bone marrow function define protocol . 8 . Ability understand willingness sign write informed consent document . 9 . All study participant must register mandatory RevAssist® program , willing able comply requirement RevAssist® . 10 . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prior prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . 11 . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin . 1 . Patients chemotherapy radiotherapy within 4 week receive monoclonal antibody within 6 week prior enter study recover adverse event due agent administer 4 week earlier . 2 . Patients may receive investigational agent anticancer agent treatment . 3 . History allergic reaction attribute compound similar chemical biologic composition ofatumumab lenalidomide . 4 . Uncontrolled concomitant illness . 5 . Pregnant woman exclude study lenalidomide believe teratogenic . 6 . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction ofatumumab lenalidomide . 7 . Prior treatment lenalidomide 8 . Evidence laboratory TLS CairoBishop Definition Tumor Lysis Syndrome . Subjects may enrol upon correction electrolyte abnormality . 9 . All patient undergo screen hepatitis B may may eligible base result outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Relapsed chronic lymphocytic leukemia</keyword>
</DOC>